Core B. Clinical Translational Core

项目总结-临床翻译核心 本申请寻求资金，以继续智力和发展研究所 残疾人研究中心（IDDRC）在加州大学戴维斯分校。IDDRC于2013年启动 并且是网络中14个IDDRC中最新的一个。临床翻译核心（CTC）旨在建立 并保持一个最佳的运作框架，用于招募，诊断评估，神经行为， 表征，并将表型映射到各种临床应用的潜在生物学机制。 人口数量。反恐委员会将处理五个具体目标。目标1是加强招聘各种各样的 参与者这一目标将通过系统的社区参与和不断增加的参与者登记来实现 包括多个民族、种族和经济背景，包括非典型和典型人群 跨越了很大的年龄跨度。目的2是提供人类参与者的行为和诊断特征。 这一目标将通过提供有经验的临床医生进行专门评估来实现， 就最佳做法的研究提供咨询意见，提供标准化措施管理方面的培训， 可靠性和监控管理的保真度，以及通过提供专业的测试空间， 将研究者与临床试验专业知识联系起来。目标3是提供进入最先进的“深层 表型分析”工具和基因组学方面的专业知识。这一目标将通过提供工具和培训来实现， 参与者的表型表征，提供深度表型分析的最新创新， IDDRC研究人员的基因组学。目标4是支持将技术纳入研究，特别是 远程保健方法，可以导致可扩展的，可获得的，具有成本效益的治疗缺碘症的条件。 这一目标将通过提供现场高水平的研究信息技术支持和获得全方位的 加州大学戴维斯分校健康中心的技术和专业知识。目的5是方便生物标本的收集和分析 并促进IDDRC项目之间的共享。这一目标将通过提供 放血服务以及使用核心管理冷冻库储存生物标本的机会和激励措施 以及MIND IDDRC生物和分子分析核心和MIND研究所基因组的链接 医学计划。拟议的气候技术中心与前一个供资期相比已大大扩大， 其中最显著的变化是深度表型和测量传播的整合 以前的神经行为分析核心的功能，这使得我们重新命名这个扩展的核心， CTCx。CTC的主任是Sally Ozonoff博士。

PROJECT SUMMARY – CLINICAL TRANSLATIONAL CORE The present application seeks funding to continue the MIND Institute Intellectual and Developmental Disabilities Research Center (IDDRC) at the University of California, Davis. The IDDRC was launched in 2013 and is the newest of the 14 IDDRCs in the network. The Clinical Translational Core (CTC) is designed to establish and maintain an operational framework that is optimal for recruitment, diagnostic assessment, neurobehavioral characterization, and mapping of phenotypes to underlying biological mechanisms for a diverse range of clinical populations. The CTC will address five specific aims. Aim 1 is to enhance recruitment of a diverse range of participants. This aim will be met through systematic community engagement and a growing participant registry that includes multiple ethnicities, races, and economic backgrounds with both atypical and typical populations across a wide age span. Aim 2 is to provide behavioral and diagnostic characterization of human participants. This aim will be met by providing access to experienced clinicians who can conduct specialized evaluations, advise studies in best practices, provide training in administration of standardized measures, establish initial reliability, and monitor administration fidelity, as well as by providing access to specialized testing space and connect investigators with clinical trials expertise. Aim 3 is to provide access to state-of-the-art “deep phenotyping” tools and expertise in genomics. This aim will be met by offering tools and training to enhance phenotypic characterization of participants, making available recent innovations in deep phenotyping and genomics to IDDRC investigators. Aim 4 is to support the integration of technology into research, especially telehealth methodologies that can lead to scalable, accessible, and cost-effective treatments for IDD conditions. This aim will be met by providing on-site high-level research IT support and access to the full array of technologies and expertise at UC Davis Health. Aim 5 is to facilitate collection and analysis of biospecimens from human participants and promote sharing across IDDRC projects. This aim will be met by providing phlebotomy services and access and incentives to use a core-managed freezer library for biospecimen storage as well as by links to the MIND IDDRC Biological and Molecular Analysis Core and the MIND Institute Genomic Medicine Program. The proposed CTC has been significantly expanded relative to the previous funding period, with the most significant change being the integration of the deep phenotyping and measure dissemination functions of the previous Neurobehavioral Analysis Core, which has led us to rename this expanded core, the CTCx. The Director of the CTC is Sally Ozonoff, PhD.